Company Overview
Snapshot
Founded in August 2013 by Amit Dar, Neurolief operates with 11–50 employees. The company has raised $17.05M across 4 funding rounds from 5 investors. In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy for adults with depression.
Business overview
Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders, focusing on a digital therapeutics platform of clinically proven neuromodulation-based solutions. Its core product, Relivion, is a noninvasive multichannel brain neuromodulation system that delivers precise, personalized care by stimulating occipital and trigeminal nerves. This technology aims to modulate brain networks associated with pain and mood control, serving markets in Health Tech & Life Sciences, particularly in digital healthcare and digital therapeutics.
Strategic signal
In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy for adults whose depression was not adequately improved by antidepressants. This approval is a significant regulatory milestone, validating the company's technology for a broader application beyond migraine treatment and signaling strong potential for market expansion in mental health care.
Log in to access full profile ›Company Intelligence Q&A
- What is Neurolief's primary focus?
- Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders, utilizing a digital therapeutics platform of neuromodulation-based solutions.
- What is the Relivion system?
- Relivion is Neurolief's noninvasive multichannel brain neuromodulation system designed for treating neurological and neuropsychiatric disorders, delivering stimulation to specific nerves for pain and mood control.
- When did Neurolief receive FDA PMA approval for depression treatment?
- In January 2026, Neurolief received FDA PMA approval for its at-home brain neuromodulation therapy for adults whose depression was not adequately improved by antidepressants.
- Did Neurolief receive a CE Mark for its Relivion device?
- Yes, in July 2019, Neurolief received the CE Mark for Relivion, its non-invasive, adaptive neuromodulation digital treatment for migraine.
- Has Neurolief secured any strategic investments recently?
- In August 2025, BrainsWay invested in Neurolief to expand its total addressable market through a strategic investment in neuromodulation systems development.